These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17438112)

  • 1. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
    Feng FY; Lopez CA; Normolle DP; Varambally S; Li X; Chun PY; Davis MA; Lawrence TS; Nyati MK
    Clin Cancer Res; 2007 Apr; 13(8):2512-8. PubMed ID: 17438112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
    Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
    Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
    Caponigro F
    Anticancer Drugs; 2004 Apr; 15(4):311-20. PubMed ID: 15057134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
    Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
    J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
    Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.
    Chun PY; Feng FY; Scheurer AM; Davis MA; Lawrence TS; Nyati MK
    Cancer Res; 2006 Jan; 66(2):981-8. PubMed ID: 16424033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Brockstein B; Lacouture M; Agulnik M
    J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts.
    Bozec A; Formento P; Lassalle S; Lippens C; Hofman P; Milano G
    Br J Cancer; 2007 Jul; 97(1):65-72. PubMed ID: 17592499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.